Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading
- 14 April 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 119 (14), 1933-1940
- https://doi.org/10.1161/circulationaha.108.818617
Abstract
Background— The glycoprotein IIb/IIIa receptor inhibitor abciximab has improved the efficacy of primary percutaneous coronary interventions in patients with acute myocardial infarction. However, it is not known whether abciximab remains beneficial after adequate clopidogrel loading in patients with acute ST-segment–elevation myocardial infarction. Methods and Results— A total of 800 patients with acute ST-segment–elevation myocardial infarction within 24 hours from symptom onset, all treated with 600 mg clopidogrel, were randomly assigned in a double-blind fashion to receive either abciximab (n=401) or placebo (n=399) in the intensive care unit before being sent to the catheterization laboratory. The primary end point, infarct size measured by single-photon emission computed tomography with technetium-99m sestamibi before hospital discharge, was 15.7±17.2% (mean±SD) of the left ventricle in the abciximab group and 16.6±18.6% of the left ventricle in the placebo group ( P =0.47). At 30 days, the composite of death, recurrent myocardial infarction, stroke, or urgent revascularization of the infarct-related artery was observed in 20 patients in the abciximab group (5.0%) and 15 patients in the placebo group (3.8%) (relative risk, 1.3; 95% CI, 0.7 to 2.6; P =0.40). Major bleeding complications were observed in 7 patients in each group (1.8%). Conclusion— Upstream administration of abciximab is not associated with a reduction in infarct size in patients presenting with acute myocardial infarction within 24 hours of symptom onset and receiving 600 mg clopidogrel.Keywords
This publication has 36 references indexed in Scilit:
- Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysisHeart, 2008
- Evolution of Left Ventricular Ejection Fraction and its Relationship to Infarct Size After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2007
- Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-upEuropean Heart Journal, 2007
- Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of ClopidogrelCirculation, 2005
- Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary InterventionCirculation, 2005
- A randomized trial comparing phosphorylcholine‐coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteriesJournal of Internal Medicine, 2004
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trialThe Lancet, 2002
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Incidence and Importance of Thrombolysis in Myocardial Infarction Grade 3 Flow After Primary Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial InfarctionThe American Journal of Cardiology, 1996